Evidence map›Paper›PMID 40243387›Full record

ReviewPediatric pulmonology2025

Pediatric Pulmonology 2024 Year in Review: Rare and Diffuse Lung Disease.

Pi Chun Cheng, Deborah R Liptzin, Katiana Garagozlo, Andrew T Barber

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pi Chun ChengDivision of Pediatric Pulmonology, Allergy, and Sleep Medicine, Riley Hospital for Children, Indianapolis, Indiana, USA.ORCID http://orcid.org/0000-0002-2809-5799
Deborah R LiptzinUniversity of Washington School of Mediine Department of Pediatrics, Seattle, Washington, USA.ORCID http://orcid.org/0000-0002-3667-1856
Katiana GaragozloDepartment of Pediatrics, Division pf Pediatric Pulmonology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.ORCID http://orcid.org/0009-0004-8437-7979
Andrew T BarberVirginia Commonwealth University, Richmond, USA.

Funding

The authors received no specific funding for this study.
6 · The paper itself

Abstract

The field of pediatric rare and diffuse lung diseases continues to advance, with ongoing research deepening our understanding of the diagnosis and treatment of conditions such as children's interstitial and diffuse lung disease (chILD), non-cystic fibrosis (CF) bronchiectasis, and pulmonary complications of childhood cancer. Recent publications in Pediatric Pulmonology and other journals in 2024 have highlighted new insights into the pathophysiology, disease progression, and emerging diagnostic tools for these rare lung conditions, as well as innovative therapeutic approaches. This review features these important advancements within the context of current diagnostic practices and clinical care for pediatric patients with rare and diffuse lung diseases.

Indexed as

Lung DiseasesPulmonary MedicineRare DiseasesChildHumansLung Diseases, InterstitialPediatricsbronchiectasisbronchiolitis obliterans syndromeinterstitial lung diseaseprimary ciliary dyskinesiastem cell transplantation

Identifiers

PMID40243387
PMCPMC12005123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.